This winter, CCADD welcomes six interns- Minsol Kim, Suhyun An, Seo-Yoon Jang, Seeun Park, Yura Choi and Nayoung Ku -  for the 2025 Winter Internship Program.

Minsol Kim is majoring in veterinary medicine at Seoul National University. She is interested in exploring the application of domain knowledge in the process of AI model development by utilizing her knowledge of pharmacology, toxicology, and physiology. Her goal is to build a solid foundation in AI and gain hands-on experience analyzing clinical data and investigating the drug development process. Through the 2025 CCADD winter internship program, she aims to explore potential career paths in the field of drug discovery.

Suhyun An is a student majoring in Stem Cell and Regenerative Biotechnology at Konkuk University. She previously worked as an undergraduate researcher in the Immunopharmacology Laboratory at Seoul National University College of Medicine, where she studied drug toxicity. Her current research interests include Drug-Drug Interactions (DDIs) and drug repurposing using artificial intelligence (AI). Her previous training primarily involved wet lab research. The CCADD internship will allow her to gain experience in data science applied to drug development, which will serve as a critical foundation for achieving her future research goals.

Seo-Yoon Jang is majoring in Systems Biotechnology at Chung-Ang University. She has a keen interest in AI and data science, which led her to complete the 2024 Boostcourse <DATA SCIENCE PROJECTS> coaching study program. Subsequently, she developed an interest in drug delivery and interned at the Lab of Drug Delivery and Cell Therapy at Sungkyunkwan University School of Medicine. Her growing passion for integrating AI into drug development led her to a winter internship at the CCADD. Through this internship, she aims to gain proficiency in data analysis tools and deepen her domain knowledge, with the goal of becoming a researcher specializing in AI-driven drug development.

Seeun Park is a senior at Yonsei University, double majoring in Biotechnology and Public Administration. She is willing to explore clinical pharmacology and regulatory science during this winter internship program. With passion in healthcare and safety, she focuses on gaining more experience and knowledge on artificial intelligence for clinical drug development and more specifically epigenetic study and policy analysis in Korea. It is her goal to work on expertise for the improvement of disease prevention and control.

Yura Choi is an undergraduate student in the Department of Chemistry at Kyung Hee University. She is passionate about AI-driven drug development, applying data science to pharmaceutical research. Through the LAIDD program, she has gained valuable insights into how AI can be applied to drug development. She aims to contribute to drug development and explore innovative therapeutic modalities by leveraging AI-driven data analysis. Currently, she is participating in the CCADD winter internship to strengthen her AI and data science expertise and deepen her understanding of research in drug development.

We hope that during their summer internship, they will build confidence in their area of expertise, develop independent learning skills to explore new knowledge, and dedicate their enthusiasm to gaining a comprehensive understanding of drug development and regulatory science throughout these two months.

On December 27th, 2023, CCADD held the year-end workshop at Front1, a startup hub at the heart of Seoul, where PMACH is based. This year, Prof. Howard Lee and the members of CCADD were joined by PMATCH and Dr. Siun Kim. The workshop went on in a dynamic atmosphere, welcoming both Prof. Howard’s part-time student and the interns for the upcoming internship program.

After a brief ice-breaking time, the main session started with a recap of the accomplishments of 2023, reflecting on the overall trajectory. Prof. Howard commended CCADD’s continuous growth in both research and publications. As preparation for 2024, the following session outlined a roadmap, encompassing detailed research ideas and plans for conference to attend in 2024.

The spotlight then turned to CCADD interns. Three passionate interns—Tang Chao, Seorin Choi, and Yunha Noh—who will join the 2024 winter internship program introduced themselves through "Who am I" presentations. Following this, Yujin expressed her aspirations for the path ahead as a new CCADD graduate research student. The workshop proceeded with a lecture on the challenges faced by postdoctoral researchers and strategies for maintaining a healthy mindset among graduate students.

Dr. Siun Kim took a special session to share insights into his post-doctoral journey following graduation. Delivering a lecture on the trending topic of "LLMs in medicine and drug development", he provided valuable perspectives and briefly introduced his ongoing research projects. He candidly shared reflections on the first-year post doc., emphasizing the professional commitment required in the field of research.

Finally, PMATCH summarized their achievements in 2023 and anticipated the upcoming year's developments. With the successful launch of the 'BATTERY' app and a triumphant debut at CES^® 2023, PMATCH envisions a promising future with new team members. Yoomin Jeon, the Chief Technology Officer of PMATCH, expressed her commitment to meeting user’s needs as a must-have app.

The workshop concluded with a keynote address by Prof. Howard. Introducing new trends in 2024, he emphasized the significance of adjusting our research focus and domain knowledge to take another leap forward. Prof. Howard’s central message highlighted 2024 as a pivotal year for CCADD's rebound and PMATCH's inaugural year of growth. 

Hardened by the CCADD internship, they took a big leap from being interns to graduate students at the Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, Seoul National University.

During the internship, they were distilled into their purest passion for research in drug development, and combining cutting-edge technology with drug development was the idea that opened the door for both.

As much as they will align nicely with the rest of the team in terms of research interest, we are also excited that they will add a new of diversity to the already diverse CCADD family.

Again, CCADD congratulates them on having taken the important first step to their goals. CCADD will blow the wind at their backs so that they can sail forth and contribute to the greater good of the team and the SNU community at large.